(NASDAQ: #MBX)
#MBXBio initiates its first-in-human Phase 1 trial of MBX‑4291, a once-monthly obesity therapy co‑agonist targeting GLP‑1/GIP receptors with improved tolerability. First patient dosed; topline data expected in 2027.
prismmarketview.com/mbx-bioscien...
0
0
0
0